Hormone use and risk for lung cancer: A pooled analysis from the International Lung Cancer Consortium (ILCCO)

British Journal of Cancer

Volumn 109, Issue 7, 2013, Pages 1954-1964

  Pesatori, A C ^a,b   Carugno, M ^a,b   Consonni, D ^b   Hung, R J ^c   Papadoupolos, A ^d,e   Landi, M T ^f   Brenner, H ^g   Muller H ^g   Harris, C C ^f   Duell, E J ^h   Andrew, A S ⁱ   McLaughlin, J R ^c,j   Schwartz, A G ^k   Wenzlaff, A S ^k   Stucker, I ^d,e  

^a UNIVERSITY OF MILAN   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c MOUNT SINAI HOSPITAL   (Canada)

^d CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^e UNIVERSITÉ PARIS SACLAY   (France)

^f NATIONAL CANCER INSTITUTE   (United States)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^h CATALAN INSTITUTE OF ONCOLOGY   (Spain)

ⁱ DARTMOUTH MEDICAL SCHOOL   (United States)

^j PUBLIC HEALTH ONTARIO   (Canada)

^k WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

exogenous hormones; hormone replacement therapy; lung cancer; oral contraceptives; pooled analysis

Indexed keywords

ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ADULT; AGED; ARTICLE; BIRTH CONTROL; BODY MASS; CANCER RISK; CONTROLLED STUDY; FEMALE; HORMONE SUBSTITUTION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MENOPAUSE; ORAL CONTRACEPTIVE USE; OVARIECTOMY; PRIORITY JOURNAL; RISK REDUCTION; SMOKING; SMOKING CESSATION; SMOKING HABIT; TREATMENT DURATION; UNDERWEIGHT;

ADENOCARCINOMA; AGED; CARCINOMA, SQUAMOUS CELL; CONTRACEPTIVES, ORAL; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; PROGESTINS; RISK; SMALL CELL LUNG CARCINOMA;

EID: 84885174938     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.506     Document Type: Article

References (50)

1. Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, Ahlbom A (2005) Calculating measures of biological interaction. Eur J Epidemiol 20(7): 575-579.
2. Baik CS, Strauss GM, Speizer FE, Feskanich D (2010) Reproductive factors, hormone use, and risk for lung cancer in postmenopausal women, the Nurses' Health Study. Cancer Epidemiol Biomarkers Prev 19(10): 2525-2533.
3. Blackman JA, Coogan PF, Rosenberg L, Strom BL, Zauber AG, Palmer JR, Langenberg P, Shapiro S (2002) Estrogen replacement therapy and risk of lung cancer. Pharmacoepidemiol Drug Saf 11(7): 561-567.
4. Brenner DR, Hung RJ, Tsao MS, Shepherd FA, Johnston MR, Narod S, Rubenstein W, McLaughlin JR (2010) Lung cancer risk in never-smokers: a population-based case-control study of epidemiologic risk factors. BMC Cancer 10: 285.
5. Brinton LA, Gierach GL, Andaya A, Park Y, Schatzkin A, Hollenbeck AR, Spitz MR (2011) Reproductive and hormonal factors and lung cancer risk in the NIH-AARP Diet and Health Study cohort. Cancer Epidemiol Biomarkers Prev 20(5): 900-911.
6. Chen GG, Zeng Q, Tse GM (2008) Estrogen and its receptors in cancer. Med Res Rev 28(6): 954-974.
7. Chen KY, Hsiao CF, Chang GC, Tsai YH, Su WC, Perng RP, Huang MS, Hsiung CA, Chen CJ, Yang PC, Group GS (2007) Hormone replacement therapy and lung cancer risk in Chinese. Cancer 110(8): 1768-1775.
8. Chlebowski RT (2009) Menopausal hormone therapy, hormone receptor status, and lung cancer in women. Semin Oncol 36(6): 566-571.
9. Chlebowski RT, Anderson GL, Manson JE, Schwartz AG, Wakelee H, Gass M, Rodabough RJ, Johnson KC, Wactawski-Wende J, Kotchen JM, Ockene JK, O'Sullivan MJ, Hubbell FA, Chien JW, Chen C, Stefanick ML (2010) Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst 102(18): 1413-1421.
10. Clague J, Reynolds P, Sullivan-Halley J, Ma H, Lacey Jr JV, Henderson KD, Ursin G, West D, Chang S, Delclos GL, Du XL, Forman MR, Bernstein L (2011) Menopausal hormone therapy does not influence lung cancer risk: results from the California Teachers Study. Cancer Epidemiol Biomarkers Prev 20(3): 560-564.
11. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10(1): 101-129.
12. Cutolo M, Brizzolara R, Atzeni F, Capellino S, Straub RH, Puttini PC (2010) The immunomodulatory effects of estrogens: clinical relevance in immune-mediated rheumatic diseases. Ann NY Acad Sci 1193: 36-42.
13. Delaunay F, Pettersson K, Tujague M, Gustafsson JA (2000) Functional differences between the amino-terminal domains of estrogen receptors alpha and beta. Mol Pharmacol 58(3): 584-590.
14. Donington JS, Colson YL (2011) Sex and gender differences in non-small cell lung cancer. Semin Thorac Cardiovasc Surg 23(2): 137-145.
15. Egger M, Smith GD, Altman DG (2001) Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd edn, BMJ: London.
16. Elliott AM, Hannaford PC (2006) Use of exogenous hormones by women and lung cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study. Contraception 73(4): 331-335.
17. Fritz AG, Percy C, Jack A, Shanmugaratnam K, Sobin L, Parkin DM, Whelan S (2000) International Classification of Diseases for Oncology. 3rd edn, World Health Organization: Geneva, Switzerland.
18. Greiser CM, Greiser EM, Doren M (2010) Menopausal hormone therapy and risk of lung cancer-Systematic review and meta-analysis. Maturitas 65(3): 198-204.
19. Hannaford PC, Iversen L, Macfarlane TV, Elliott AM, Angus V, Lee AJ (2010) Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ 340: c927.
20. Heck JE, Andrew AS, Onega T, Rigas JR, Jackson BP, Karagas MR, Duell EJ (2009) Lung cancer in a U.S. population with low to moderate arsenic exposure. Environ Health Perspect 117(11): 1718-1723.
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414): 557-560.
22. Hoffmann K, Krause C, Seifert B (2001) The German Environmental Survey 1990/92 (GerES II): primary predictors of blood cadmium levels in adults. Arch Environ Health 56(4): 374-379.
23. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280(7): 605-613.
24. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2): 69-90.
25. Kabat GC, Miller AB, Rohan TE (2007) Reproductive and hormonal factors and risk of lung cancer in women: a prospective cohort study. Int J Cancer 120(10): 2214-2220.
26. Kaiser U, Hofmann J, Schilli M, Wegmann B, Klotz U, Wedel S, Virmani AK, Wollmer E, Branscheid D, Gazdar AF, Havemann K (1996) Steroidhormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer 67(3): 357-364.
27. Kiyohara C, Ohno Y (2010) Sex differences in lung cancer susceptibility: a review. Gend Med 7(5): 381-401.
28. Kreuzer M, Gerken M, Heinrich J, Kreienbrock L, Wichmann HE (2003) Hormonal factors and risk of lung cancer among women? Int J Epidemiol 32(2): 263-271.
29. Leffondré K, Abrahamowicz M, Xiao Y, Siemiatycki J (2006) Modelling smoking history using a comprehensive smoking index: application to lung cancer. Stat Med 25(24): 4132-4146.
30. Liu Y, Inoue M, Sobue T, Tsugane S (2005) Reproductive factors, hormone use and the risk of lung cancer among middle-aged never-smoking Japanese women: a large-scale population-based cohort study. Int J Cancer 117(4): 662-666.
31. Meinhold CL, Berrington de Gonzalez A, Bowman ED, Brenner AV, Jones RT, Lacey Jr JV, Loffredo CA, Perlmutter D, Schonfeld SJ, Trivers GE, Harris CC (2011) Reproductive and hormonal factors and the risk of nonsmall cell lung cancer. Int J Cancer 128(6): 1404-1413.
32. Meireles SI, Esteves GH, Hirata Jr R, Peri S, Devarajan K, Slifker M, Mosier SL, Peng J, Vadhanam MV, Hurst HE, Neves EJ, Reis LF, Gairola CG, Gupta RC, Clapper ML (2010) Early changes in gene expression induced by tobacco smoke: evidence for the importance of estrogen within lung tissue. Cancer Prev Res 3(6): 707-717.
33. Oh SW, Myung SK, Park JY, Lym YL, Ju W (2010) Hormone therapy and risk of lung cancer: a meta-analysis. J Women Health 19(2): 279-288.
34. Omoto Y, Kobayashi Y, Nishida K, Tsuchiya E, Eguchi H, Nakagawa K, Ishikawa Y, Yamori T, Iwase H, Fujii Y, Warner M, Gustafsson JA, Hayashi SI (2001) Expression, function, and clinical implications of the estrogen receptor beta in human lung cancers. Biochem Biophys Res Commun 285(2): 340-347.
35. Pesatori AC, Carugno M, Consonni D, Caporaso NE, Wacholder S, Tucker M, Landi MT (2013) Reproductive and hormonal factors and the risk of lung cancer: The EAGLE study. Int J Cancer J 132(11): 2630-2639.
36. Ramnath N, Menezes RJ, Loewen G, Dua P, Eid F, Alkhaddo J, Paganelli G, Natarajan N, Reid ME (2007) Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of a case-control study. Oncology 73(5-6): 305-310.
37. Richiardi L, Barone-Adesi F, Merletti F, Pearce N (2008) Using directed acyclic graphs to consider adjustment for socioeconomic status in occupational cancer studies. J Epidemiol Commun Health 62(7): e14.
38. Rodriguez C, Spencer Feigelson H, Deka A, Patel AV, Jacobs EJ, Thun MJ, Calle EE (2008) Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev 17(3): 655-660.
39. Rothman KJ (2002) Epidemiology: An Introduction. Oxford University Press: USA.
40. Schabath MB, Wu X, Vassilopoulou-Sellin R, Vaporciyan AA, Spitz MR (2004) Hormone replacement therapy and lung cancer risk: a case-control analysis. Clin Cancer Res 10(1 Pt 1): 113-123.
41. Schwartz AG, Wenzlaff AS, Prysak GM, Murphy V, Cote ML, Brooks SC, Skafar DF, Lonardo F (2007) Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol 25(36): 5785-5792.
42. Seow A, Koh WP, Wang R, Lee HP, Yu MC (2009) Reproductive variables, soy intake, and lung cancer risk among nonsmoking women in the Singapore Chinese Health Study. Cancer Epidemiol Biomarkers Prev 18(3): 821-827.
43. Siegfried JM (2010) Early changes in pulmonary gene expression following tobacco exposure shed light on the role of estrogen metabolism in lung carcinogenesis. Cancer Prev Res 3(6): 692-695.
44. Slatore CG, Chien JW, Au DH, Satia JA, White E (2010) Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol 28(9): 1540-1546.
45. Stabile LP, Lyker JS, Gubish CT, Zhang W, Grandis JR, Siegfried JM (2005) Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects. Cancer Res 65(4): 1459-1470.
46. Taioli E, Wynder EL (1994) Re: Endocrine factors and adenocarcinoma of the lung in women. J Natl Cancer Inst 86(11): 869-870.
47. Tanko LB, Christiansen C (2004) An update on the antiestrogenic effect of smoking: a literature review with implications for researchers and practitioners. Menopause 11(1): 104-109.
48. Vessey M, Yeates D, Flynn S (2010) Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception 82(3): 221-229.
49. Weiss JM, Lacey Jr JV, Shu XO, Ji BT, Hou L, Yang G, Li H, Rothman N, Blair A, Gao YT, Chow WH, Zheng W (2008) Menstrual and reproductive factors in association with lung cancer in female lifetime nonsmokers. Am J Epidemiol 168(11): 1319-1325.
50. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X (1999) Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 91(2): 151-156.